Novo Nordisk halts work on cell therapy for diabetes to cut costs, Bloomberg News reportsReuters • 10/10/25
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?Zacks Investment Research • 10/10/25
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?Zacks Investment Research • 10/09/25
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drugFast Company • 10/09/25
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 BillionBenzinga • 10/09/25
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion BuyoutInvestors Business Daily • 10/09/25
Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2BProactive Investors • 10/09/25
Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver diseaseMarket Watch • 10/09/25
Novo Nordisk to buy Akero for up to $5.2 billion as new CEO bets on liver drug candidateCNBC • 10/09/25
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolioGlobeNewsWire • 10/09/25